Cargando…
Therapeutic vaccine for chronic diseases after the COVID-19 Era
There is currently a respiratory disease outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After rapid development, RNA vaccines and adenoviral vector vaccines were approved within a year, which has demonstrated the strong impact of preventing infectious diseases using...
Autores principales: | Nakagami, Hironori, Hayashi, Hiroki, Shimamura, Munehisa, Rakugi, Hiromi, Morishita, Ryuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184354/ https://www.ncbi.nlm.nih.gov/pubmed/34099884 http://dx.doi.org/10.1038/s41440-021-00677-3 |
Ejemplares similares
-
A novel angiotensin II peptide vaccine without an adjuvant in mice
por: Nakamaru, Ryo, et al.
Publicado: (2021) -
Development of an IL-17A DNA Vaccine to Treat Systemic Lupus Erythematosus in Mice
por: Koriyama, Hiroshi, et al.
Publicado: (2020) -
Prevention of bleomycin-induced pulmonary fibrosis by a RANKL peptide in mice
por: Ju, Nan, et al.
Publicado: (2022) -
AJP001, a novel helper T‐cell epitope, induces a humoral immune response with activation of innate immunity when included in a peptide vaccine
por: Tenma, Akiko, et al.
Publicado: (2019) -
Preventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimod-induced psoriasis
por: Ju, Nan, et al.
Publicado: (2019)